Joaquin Duato, J&J CEO (Amir Hamja/Bloomberg via Getty Images)
November 30, 2023 03:10 PM EST
Deals
Pharma

J&J ac­quires Cal­i­for­nia med­ical de­vice com­pa­ny for $400M

Nicole DeFeudis

Editor

John­son & John­son put down $400 mil­lion up­front to ac­quire Lam­i­nar, a med­ical de­vice com­pa­ny fo­cused on re­duc­ing the risk of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times